• Press Release

BIA welcomes Minister’s Reassurance on the Patents (Amendment) (EU Exit) Regulations 2018

The Government last night committed to further consultation with the BIA on the UK’s future Intellectual Property rights regime in the event of a ‘no deal’ Brexit following concerns raised in the House of Lords. 

2018 a record year for UK biotech fundraising

New figures published today (Thursday 24 January 2019) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised a record £2.2 billion from investors in 2018. The total is the best ever recorded by the trade association and almost double that raised in 2017. The data is presented in the report Confident capital: backing UK biotech and launched by the Exchequer Secretary to the Treasury, Robert Jenrick MP, at the BIA's Strategic Technologies event in central London today.

BIA response to Health Secretary's plan to contain and control AMR

Steve Bates OBE, CEO of the BIA said:  “It’s great to see the UK government and NHS committed to exploring a new payment model for antibiotics in our market. The UK took a lead in putting Anti Microbial Resistance (AMR) on the global agenda and it’s really good to see it taking a first mover advantage on innovative pricing and reimbursement for AMR. 

BIA welcomes the announcement of Nicola Blackwood as new Under-Secretary of State for Health

The BIA welcomes the announcement of Nicola Blackwood as new Parliamentary Under-Secretary of State for Health. BIA CEO, Steve Bates OBE, said: “As a former health minister and former chair of the science and technology committee, and serving as a board member of Eagle Genomics, Nicola knows our sector well and is well-placed to hit the ground running. We had a strong relationship with Nicola when she was minister for health, and we look forward to working with her to ensure the UK stays a world-leader in the life sciences.”

BIA responds to the new letter from Government on the medicine supply contingency plan programme

Today the Health Secretary Matt Hancock has written to pharmaceutical companies to update them on progress made on human medicines supply in March 2019 “no deal scenario” with some updates to the Government planning assumptions.

BIA responds to second Life Sciences Sector Deal

Today the government has published the second Life Sciences Sector Deal. The document details both public and private sector investments into the sector, including a £1bn research and development investment from BIA member company UCB and a new partnership between government and industry using artificial intelligence to develop the next generation of treatments.

Action Medical Research for children named BIA Charity of the Year 2019

The BioIndustry Association has today announced that Action Medical Research for children will be its Charity of the Year for 2019. The partnership will be formally launched at the BIA Gala Dinner on 24 January 2019. Proceeds from a silent auction, table donations and pledges on the night will be donated to Action Medical Research for children, and attendees will hear from Simon Harriss, dad to 10-year-old Lily who has a devastating neurological condition called BPAN.

All Party Parliamentary Group to raise the profile of the UK Life Sciences sector

This week marked the relaunch of the All Party Parliamentary Group (APPG) for Life Sciences. Chaired by Daniel Zeichner MP, the APPG will raise awareness of UK life sciences among parliamentarians and explore the challenges and opportunities facing the sector.

NHS, Pharma and Biotech Industries call on Government to protect patients in future UK-EU relationship

A coalition from the UK’s health sector say Brexit negotiators have a responsibility to protect 500 million patients on both sides of the Channel.  The group is calling on both sides to make patients and public health central to the Political Declaration for the future relationship between the UK and the EU.

BIA responds to the announcement that UK Cabinet has approved the draft Brexit deal

In response to the announcement that UK Cabinet has approved the draft Brexit deal, BIA CEO, Steve Bates, said: "We welcome this week's progress on Brexit discussions with the initial agreement between the EU and UK on a withdrawal agreement and the political agreement on the outline of a future relationship. The BIA will now monitor and inform its members of the political debate that will ensue in the finely balanced UK parliament. There is significant detail to digest and we are engaging with members and others to understand the implications of the deal for the life sciences sector, and plan to produce a detailed briefing on this next week.